Disc Medicine Inc Quick Ratio (IRON) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Disc Medicine Inc   (NASDAQ: IRON)

Disc Medicine Inc 's Quick Ratio

IRON's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 19.87 below Disc Medicine Inc average.

Within Major Pharmaceutical Preparations industry 5 other companies have achieved higher Quick Ratio than Disc Medicine Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 55 to 90.

Explain Quick Ratio?
How much Cash & cash equivalents IRON´s has?
What are IRON´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/IRON/financial-strength
https://api.csimarket.com/api/v1/companies/IRON/fundamentals
https://api.csimarket.com/api/v1/companies/IRON/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
IRON Quick Ratio (Sep 30 2026)
Q3		 (Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 86.91 %
Y / Y Cash & cash equivalent Change 10.86 %
Quick Ratio MRQ 19.87
IRON's Total Ranking # 90
Seq. Current Liabilities Change 13.18 %
Seq. Cash & cash equivalent Change -48.92 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 6
Healthcare Sector # 10
Overall Market # 90


Quick Ratio Statistics
High Average Low
89.32 28.67 1.4
(Sep 30 2022)   (Dec 31 2020)




Financial Statements
Disc Medicine Inc 's Current Liabilities $ 34 Millions Visit IRON's Balance sheet
Disc Medicine Inc 's Cash & cash equivalent $ 683 Millions Visit IRON's Balance sheet
Source of IRON's Sales Visit IRON's Sales by Geography


Cumulative Disc Medicine Inc 's Quick Ratio

IRON's Quick Ratio for the trailling 12 Months

IRON Quick Ratio

 (Sep 30 2026)
12 Months		 (Jun 30 2026)
12 Months 		(Mar 31 2026)
12 Months 		(Dec 31 2025)
12 Months 		(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 86.72 %
Y / Y Cash & cash equivalent TTM Growth 44.5 %
Quick Ratio TTM 32.82
Total Ranking TTM # 3363
Seq. Current Liabilities TTM Growth 17.38 %
Seq. Cash & cash equivalent TTM Growth 1.93 %

Quick ratio ranking by company, industry and sector >> Back to IRON Financial Strength Comparisons >> Go to Compare IRON Quick Ratio to its Competitors

  News about Disc Medicine Inc Quick Ratio

Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc. to Propel Clinical Advancements in Hematology.

Disc Medicine Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company specializing in treatments for serious hematologic diseases, has recently announced a significant financial milestone that positions the company for sustained growth and innovation in the field. The company secured a $200 million non-dilutive term loan facility from Hercules Capital, Inc. (NYSE:HTGC), which will support various upcoming clinical studies and enhance its balance sheet as the company prepares to present at the 66th American Society of Hematology (ASH) Annual Meeting in December 2024.Key Financial Developments:1. Non-Dilutive Financing: The $200 million loan from Hercules Capital is a crucial financial arrangement for Disc Medicine, allowing it to fund critical studies without diluting the current shareholdersn equity. 2. Strategic Use of Funds: The financing will facilitate the initiation of key clinical studies: - A confirmatory study of bitopertin for erythropoietic protoporphyria (EPP). - A Phase 2 study of DISC-0974 for anemia of myelofibrosis (MF). - A multiple-dose study for anemia in non-dialysis dependent chronic kidney disease (NDD-CKD). - A Phase 2 study of DISC-3405 in polycythemia vera (PV).

Disc Medicine Raises $178 Million through Successful Underwritten Offering of Common Stock



In a significant move towards advancing its mission of revolutionizing the treatment landscape for serious hematologic diseases, Disc Medicine, Inc., a prominent clinical-stage biopharmaceutical company, has announced the pricing of an underwritten offering of its common stock. This offering paves the way for the company to generate approximately $178.0 million in aggregate gross proceeds, representing a significant milestone in its growth strategy. The news has garnered substantial attention within the biopharmaceutical industry and underscores Disc Medicine s commitment to developing innovative therapies for patients in need.
Underwritten Offering Details:
Disc Medicine, Inc. has successfully priced the underwritten offering of 4,944,000 shares of its common stock at $36.00 per share. All of the securities being sold in the offering are offered exclusively by Disc Medicine. It is worth noting that the offering price reflects both the company s strong market positioning and investors confidence in its potential. The anticipated proceeds, which do not include underwriting discounts, commissions, and other offering expenses, are expected to significantly bolster Disc Medicine s financial strength and support the advancement of its clinical programs.

On the trailing twelve months basis Due to increase in Current Liabilities in the Q3 2026 to $34.36 millions, cumulative Quick Ratio decreased to 32.82 above the IRON average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 416 other companies have achieved higher Quick Ratio than Disc Medicine Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2122 to 3363.

Explain Quick Ratio?
How much Cash & cash equivalents IRON´s has?
What are IRON´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 417
Healthcare Sector # 848
Within the Market # 3363


trailing twelve months Quick Ratio Statistics
High Average Low
24.23 13.02 3.89
(Dec 31 2023)   (Mar 31 2026)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Rallybio Corporation  51.94 $ 90.693  Millions$ 1.746  Millions
Enliven Therapeutics Inc   45.41 $ 884.351  Millions$ 19.473  Millions
Vyne Therapeutics Inc   41.29 $ 268.860  Millions$ 6.511  Millions
Bicara Therapeutics Inc   40.75 $ 442.346  Millions$ 10.856  Millions
Xbiotech Inc   39.02 $ 105.037  Millions$ 2.692  Millions
Tango Therapeutics Inc   38.85 $ 977.503  Millions$ 25.164  Millions
Trevi Therapeutics Inc   38.05 $ 299.408  Millions$ 7.869  Millions
Fulcrum Therapeutics Inc   35.70 $ 306.545  Millions$ 8.587  Millions
Boundless Bio Inc   33.60 $ 62.894  Millions$ 1.872  Millions
Avalyn Pharma Inc   32.64 $ 422.814  Millions$ 12.955  Millions
Immix Biopharma Inc   30.89 $ 336.303  Millions$ 10.889  Millions
Minerva Neurosciences Inc   30.46 $ 76.945  Millions$ 2.526  Millions
Contineum Therapeutics Inc   30.45 $ 244.484  Millions$ 8.028  Millions
Pasithea Therapeutics Corp   29.91 $ 82.419  Millions$ 2.756  Millions
Latigo Biotherapeutics, Inc.  28.73 $ 401.241  Millions$ 13.964  Millions
Amylyx Pharmaceuticals Inc   26.44 $ 768.132  Millions$ 29.048  Millions
Climb Bio Inc   25.98 $ 205.423  Millions$ 7.906  Millions
Prothena Corporation Public Limited Company  23.73 $ 271.368  Millions$ 11.434  Millions
Silo Pharma Inc  22.91 $ 8.051  Millions$ 0.351  Millions
Innoviva Inc   22.67 $ 1,134.297  Millions$ 50.030  Millions
Silence Therapeutics Plc  22.00 $ 247.659  Millions$ 11.259  Millions
Kailera Therapeutics Inc   21.40 $ 901.454  Millions$ 42.116  Millions
Cryoport inc   20.47 $ 653.343  Millions$ 31.911  Millions
Roivant Sciences Ltd   20.30 $ 5,683.045  Millions$ 279.911  Millions
Disc Medicine Inc   19.87 $ 682.816  Millions$ 34.360  Millions
Relmada Therapeutics Inc  19.30 $ 202.123  Millions$ 10.474  Millions
Mbx Biosciences Inc   19.14 $ 481.594  Millions$ 25.167  Millions
Telomir Pharmaceuticals Inc   19.07 $ 4.516  Millions$ 0.237  Millions
Equillium Inc   18.92 $ 53.322  Millions$ 2.819  Millions
Onkure Therapeutics Inc   18.58 $ 163.305  Millions$ 8.789  Millions

Date modified: 2026-11-08T19:29:32+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.